A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies

Trial Profile

A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs BGB 3111 (Primary) ; BGB A317 (Primary)
  • Indications B cell lymphoma; Leukaemia
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 11 Nov 2016 According to a BeiGene media release, data from this trial is anticipated to be presented in 2017.
    • 29 Jun 2016 According to a BeiGene media release, the first patient has been enrolled in this trial.
    • 08 Jun 2016 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top